Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Clinical trial NCT04635995 · COMPLETED
Trial details
- NCT number
- NCT04635995
- Sponsor
- Lyvgen Biopharma Holdings Limited
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-11
- Primary completion
- 2025-12-31
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.